Analysis and impact of a multidisciplinary lymphoma virtual tumor board

References

• Taylor C, Munro AJ, Glynne-Jones R, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010;340:c951.
   PubMed Web of Science ®Google Scholar
• Kehl KL, Landrum MB, Kahn KL, et al. Tumor board participation among physicians caring for patients with lung or colorectal cancer. J Oncol Pract. 2015;11(3):e267–e278.
   PubMed Web of Science ®Google Scholar
• Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev. 2016;42:56–72.
   PubMed Web of Science ®Google Scholar
• Wright FC, De Vito C, Langer B, et al. Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer. 2007;43(6):1002–1010.
   PubMed Web of Science ®Google Scholar
• Cancer Program Standards; 2016; [cited 2019 Sep 18]. Available from: https://www.facs.org/quality-programs/cancer/coc/standards
   Google Scholar
• Multidisciplinary Cancer Management Courses (MCMC) | ASCO; 2019; [cited 2019 Sep 20]. Available from: https://www.asco.org/international-programs/international-meetings-educational-opportunities/multidisciplinary-cancer
   Google Scholar
• Sundi D, Cohen JE, Cole AP, et al. Establishment of a new prostate cancer multidisciplinary clinic: format and initial experience. Prostate. 2015;75(2):191–199.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Laheru D, Hruban RH, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol. 2008;15(8):2081–2088.
   PubMed Web of Science ®Google Scholar
• Forrest LM, McMillan DC, McArdle CS, et al. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2005;93(9):977–978.
   PubMed Web of Science ®Google Scholar
• Tyler KH, Haverkos BM, Hastings J, et al. The role of an integrated multidisciplinary clinic in the management of patients with cutaneous lymphoma. Front Oncol. 2015;5:136.
   PubMed Web of Science ®Google Scholar
• Korman H, Lanni T, Shah C, et al. Impact of a prostate multidisciplinary clinic program on patient treatment decisions and on adherence to NCCN guidelines: the William Beaumont Hospital experience. Am J Clin Oncol. 2013;36(2):121–125.
   PubMed Web of Science ®Google Scholar
• Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2014;21(4):1287–1295.
   PubMed Web of Science ®Google Scholar
• Lordan JT, Karanjia ND, Quiney N, et al. A 10-year study of outcome following hepatic resection for colorectal liver metastases – the effect of evaluation in a multidisciplinary team setting. Eur J Surg Oncol. 2009;35(3):302–306.
   PubMed Web of Science ®Google Scholar
• Stephens MR, Lewis WG, Brewster AE, et al. Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Dis Esophagus. 2006;19(3):164–171.
   PubMed Web of Science ®Google Scholar
• Keating NL, Landrum MB, Lamont EB, et al. Tumor boards and the quality of cancer care. J Natl Cancer Inst. 2013;105(2):113–121.
   PubMedGoogle Scholar
• Blayney DW. Tumor boards (Team Huddles) aren't enough to reach the goal. J Natl Cancer Inst. 2013;105(2):82–84.
   PubMedGoogle Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Cohen P, Tan AL, Penman A. The multidisciplinary tumor conference in gynecologic oncology—does it alter management? Int J Gynecol Cancer. 2009;19(9):1470–1472.
   PubMed Web of Science ®Google Scholar
• Chang JH, Vines E, Bertsch H, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the university of Pennsylvania experience. Cancer. 2001;91(7):1231–1237.
   PubMed Web of Science ®Google Scholar
• Brännström F, Bjerregaard JK, Winbladh A, et al. Multidisciplinary team conferences promote treatment according to guidelines in rectal cancer. Acta Oncol. 2015;54(4):447–453.
   PubMed Web of Science ®Google Scholar
• Wille-Jørgensen P, Sparre P, Glenthøj A, et al. Result of the implementation of multidisciplinary teams in rectal cancer. Colorectal Dis. 2013;15(4):410–413.
   PubMed Web of Science ®Google Scholar
• Davies AR, Deans DAC, Penman I, et al. The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer. Dis Esophagus. 2006;19(6):496–503.
   PubMed Web of Science ®Google Scholar
• Freeman RK, Van Woerkom JM, Vyverberg A, et al. The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer. Eur J Cardiothorac Surg. 2010;38(1):1–5.
   PubMed Web of Science ®Google Scholar
• Wheless SA, McKinney KA, Zanation AM. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg. 2010;143(5):650–654.
   PubMed Web of Science ®Google Scholar
• van Hagen P, Spaander MCW, van der Gaast A, et al. Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study. Int J Clin Oncol. 2013;18(2):214–219.
   PubMed Web of Science ®Google Scholar
• Gatcliffe T, Coleman R. Tumor board: more than treatment planning—a 1-year prospective survey. J Cancer Educ. 2008;23(4):235–237.
   PubMed Web of Science ®Google Scholar
• Newman EA, Guest AB, Helvie MA, et al. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer. 2006;107(10):2346–2351.
   PubMed Web of Science ®Google Scholar
• Rao K, Manya K, Azad A, et al. Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre – impact on clinical decision-making and implications for patient inclusion. BJU Int. 2014;114(Suppl. 1):50–54.
   PubMedGoogle Scholar
• Palmer G, Martling A, Cedermark B, et al. Preoperative tumour staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancer. Colorectal Dis. 2011;13(12):1361–1369.
   PubMed Web of Science ®Google Scholar
• Freeman RK, Ascioti AJ, Dake M, et al. The effects of a multidisciplinary care conference on the quality and cost of care for lung cancer patients. Ann Thorac Surg. 2015;100(5):1834–1838.
   PubMed Web of Science ®Google Scholar
• Sasse S, Bröckelmann PJ, Goergen H, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017;35(18):1999–2007.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372(17):1598–1607.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144–152.
   PubMed Web of Science ®Google Scholar
• Bachy E, Maurer MJ, Habermann TM, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132(1):49–58.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096–1101.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Jais J-P, Ghesquières H, et al. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol. 2016;91(2):179–184.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29(8):1822–1827.
   PubMed Web of Science ®Google Scholar
• Farooq U, Maurer MJ, Thompson CA, et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. Br J Haematol. 2017;179(1):50–60.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group Protocol E4402. J Clin Oncol. 2014;32(28):3096–3102.
   PubMed Web of Science ®Google Scholar
• Advani RH, Hong F, Fisher RI, et al. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015;33(17):1936–1942.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31(6):684–691.
   PubMed Web of Science ®Google Scholar
• Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549–562.
   PubMed Web of Science ®Google Scholar
• Kenderian SS, Habermann TM, Macon WR, et al. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood. 2016;127(16):1960–1966.
   PubMed Web of Science ®Google Scholar
• Evens AM, Advani R, Press OW, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol. 2013;31(32):4132–4139.
   PubMed Web of Science ®Google Scholar
• Pophali PA, Ip A, Larson MC, et al. The association of physical activity before and after lymphoma diagnosis with survival outcomes. Am J Hematol. 2018;93(12):1543–1550.
   PubMed Web of Science ®Google Scholar
• McPhail ED, Maurer MJ, Macon WR, et al. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica. 2018;103(11):1899–1907.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN guidelines insights: B-cell lymphomas, version 3.2019. J Natl Compr Canc Netw. 2019;17(6):650–661.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Wierda WG, et al. Diffuse large B-cell lymphoma version 1.2016: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(2):196–231.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Zelenetz AD, Gordon LI, et al. NCCN guidelines insights: non-Hodgkin's lymphomas, version 3.2016. J Natl Compr Canc Netw. 2016;14(9):1067–1079.
   PubMed Web of Science ®Google Scholar
• Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017;3(9):1257–1265.
   PubMed Web of Science ®Google Scholar